The NLC Health Impact Fund

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

Wavefront is revolutionizing live-cell imaging with their AI-driven computational microscope, offering a stain-free imaging technique powered by patented quantitative-phase-imaging (QPI) technology. This approach eliminates the need for costly and invasive chemical staining, preserving cell integrity with real-time visualization of cellular structures with precision and detail. Wavefront's innovative solution has transformative potential research across diverse fields, from cancer research to clinical diagnostics.

Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid treatment for peripheral neuropathy, addressing a market with over 500 million patients globally. Their GalR2 agonist delivers dual action that no current therapy offers: potent pain relief and nerve regeneration. Critically, NLV-01 does not cross the blood-brain barrier, eliminating the CNS side effects and addiction risk that limit opioids and gabapentinoids.

Sanmirna is pioneering a first-in-class microRNA inhibitor - Miristen™ - designed to eliminate leukemia stem cells while preserving healthy hematopoiesis. In December 2025, Miristen™ began dosing relapsing/resistant patients in a Phase Ia/Ib study. The study is expected to complete in 2026. Sanmirna is now planning pivotal studies in accord with FDA guidelines.

Audaxis Medical revolutionizes the treatment of stress urinary incontinence with Plielle™, a next-generation polyurethane support system. While traditional polypropylene slings often lead to chronic inflammation and tissue complications, Plielle™ offers a safer alternative by replicating the native structure and viscoelastic properties of the pelvic floor. By providing a high-performance, biocompatible solution that integrates seamlessly with human tissue, Audaxis aims to improve clinical outcomes and restore patient confidence, filling a critical gap in women’s healthcare.

Epilepsy causes uncontrolled seizures, greatly reducing quality of life and sometimes leading to early death. Over 50 million people worldwide have epilepsy, but only two-thirds respond to medication. For those with drug-resistant epilepsy, treatment options are limited and often ineffective. MIR Therapeutics is developing a new gene therapy to provide lasting and powerful seizure control for drug-resistant epilepsy patients. Their therapy delivers microRNA-335 to the affected brain regions using an AAV9 viral vector, which helps control hyperexcitability by regulating voltage-gated sodium channels. This results in fewer and less severe seizures.